These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34281590)

  • 1. Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial.
    Jensterle M; Ferjan S; Battelino T; Kovač J; Battelino S; Šuput D; Vovk A; Janež A
    Trials; 2021 Jul; 22(1):464. PubMed ID: 34281590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1, a matter of taste?
    Jensterle M; DeVries JH; Battelino T; Battelino S; Yildiz B; Janez A
    Rev Endocr Metab Disord; 2021 Dec; 22(4):763-775. PubMed ID: 33123893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
    Ishøy PL; Knop FK; Broberg BV; Baandrup L; Fagerlund B; Jørgensen NR; Andersen UB; Rostrup E; Glenthøj BY; Ebdrup BH
    BMJ Open; 2014 Jan; 4(1):e004158. PubMed ID: 24401727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).
    Sass MR; Danielsen AA; Köhler-Forsberg O; Storgaard H; Knop FK; Nielsen MØ; Sjödin AM; Mors O; Correll CU; Ekstrøm C; Vinberg M; Nielsen J; Vilsbøll T; Fink-Jensen A
    BMJ Open; 2023 Jan; 13(1):e068652. PubMed ID: 36720576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications.
    Jensterle M; Rizzo M; Janez A
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial.
    Ganeshalingam AA; Uhrenholt NG; Arnfred S; Gæde PH; Bilenberg N; Frystyk J
    BMJ Open; 2024 Mar; 14(3):e077173. PubMed ID: 38503415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.
    Jensterle M; Ferjan S; Vovk A; Battelino T; Rizzo M; Janež A
    Diabetes Res Clin Pract; 2021 Aug; 178():108935. PubMed ID: 34217774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
    Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single-blind placebo-controlled study.
    Behary P; Alessimii H; Miras AD; Tharakan G; Alexiadou K; Aldhwayan MM; Purkayastha S; Moorthy K; Ahmed AR; Bloom SR; Tan TM
    Diabetes Obes Metab; 2023 Jun; 25(6):1731-1739. PubMed ID: 36811311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
    Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
    Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.
    Koychev I; Adler AI; Edison P; Tom B; Milton JE; Butchart J; Hampshire A; Marshall C; Coulthard E; Zetterberg H; Hellyer P; Cormack F; Underwood BR; Mummery CJ; Holman RR
    BMJ Open; 2024 Jun; 14(6):e081401. PubMed ID: 38908839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
    Gallwitz B; Giorgino F
    Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
    Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
    Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.
    Mahapatra MK; Karuppasamy M; Sahoo BM
    Pharm Res; 2022 Jun; 39(6):1233-1248. PubMed ID: 35650449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.